Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer

BACKGROUND: Concurrent chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC) for patients who can tolerate it. We explored if adding erlotinib would increase the effectiveness of chemoradiotherapy without increasing toxicity in a single-arm prospective...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Radiat Oncol Biol Phys
Main Authors: Komaki, Ritsuko, Allen, Pamela K., Wei, Xiong, Blumenschein, George R., Tang, Ximing, Lee, J. Jack, Welsh, James W., Wistuba, Ignacio I., Liu, Diane D., Hong, Waun Ki
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4432249/
https://ncbi.nlm.nih.gov/pubmed/25968826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2015.02.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares